AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Know Labs Discusses Intellectual Property Strategy

January 3, 2020 GMT

SEATTLE--(BUSINESS WIRE)--Jan 3, 2020--

Know Labs, Inc. (OTCQB: KNWN) today reviewed its intellectual property strategy for investors as it moves into the 2020 calendar year. As discussed in its recent annual 10-K filing, the Company has pursued for several years an ambitious intellectual property strategy focused on patent filings, trademarks, copyrights and trade secrets.

The Company currently has 13 issued patents to which it possesses all right, title and interest. It also has an exclusive license to 9 patents owned by Allied Inventors, a spin-off subsidiary of Intellectual Ventures, the largest IP-centric fund in the world. In addition, the Company has a growing number of patents pending. That number is added to with regularity as the Company aggressively expands its patent portfolio.

The Company expects new patents covering its foundational technology to issue over time. Recently, the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on an important addition to its patent portfolio covering foundational elements of its technology.

The Company will provide detail on the scope and reach of its intellectual property patent portfolio as patents are issued.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2019, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200103005051/en/

CONTACT: Know Labs, Inc.

Jordyn Theisen

jordyn@knowlabs.co

Ph. 319-321-8470

KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY DIABETES HEALTH MEDICAL DEVICES

SOURCE: Know Labs, Inc.

Copyright Business Wire 2020.

PUB: 01/03/2020 09:00 AM/DISC: 01/03/2020 09:01 AM

http://www.businesswire.com/news/home/20200103005051/en